Otros idiomas Cabaletta Bio, Inc.

Acciones

CABA

US12674W1099

Tiempo real estimado Cboe BZX Otros sitios de cotización 21:32:17 30/04/2024			Varia. Cinco días.	Varia. 1 de enero.
10,7 ^USD	+2,15 %		-21,40 %	-53,88 %

22/03	CABALETTA BIO, INC. : Obtiene una recomendación de compra de HC Wainwright	ZM
21/03	Cabaletta Bio, Inc. Resultados del ejercicio cerrado el 31 de diciembre de 2023	CI

Otros idiomas

Desbloquee todas las noticias sobre todas las empresas: ¡No vuelvas a perderse una oportunidad de inversión rentable!

Inscripción 100% Gratuita

Cabaletta Bio, Inc. Reports Earnings Results for the Full Year Ended December 31, 2023	21/03
Cabaletta Bio Reports Fourth Quarter and Full Year 2023 Financial Results and Provides Business Update	21/03
Cabaletta Bio, Inc. Reports Earnings Results for the Fourth Quarter Ended December 31, 2023	21/03
Cabaletta Bio Gets Orphan Drug Designation From FDA For Systemic Sclerosis Treatment	20/03
Cabaletta Bio Announces FDA Granted Orphan Drug Designation to CABA-201 for Treatment of Systemic Sclerosis	20/03
Cabaletta Bio Announces FDA Granted Orphan Drug Designation to CABA-201 for Treatment of Systemic Sclerosis	20/03
North American Morning Briefing : Markets on Hold -2-	20/03
North American Morning Briefing : Stock Futures -2-	13/03
Cabaletta Bio to Participate in Upcoming Investor Conferences in March	27/02
Cabaletta Bio Secures Orphan Drug Designation for Myositis Treatment	02/02
Cabaletta Bio Gets Orphan Drug Designation for Potential Autoimmune Disease Treatment	01/02
Cabaletta, Inc. Announces FDA Grants Orphan Drug Designation to CABA-201	01/02
Cabaletta Bio Announces FDA Granted Orphan Drug Designation to CABA-201 for Treatment of Myositis	01/02
Cabaletta Bio to Participate in the Guggenheim Healthcare Talks 6th Annual Biotechnology Conference	31/01
Cabaletta Bio Gets Additional FDA Fast Track Labels For CABA-201	08/01
Cabaletta Bio Receives Additional FDA Fast Track Designations for CABA-201 in Dermatomyositis and Systemic Sclerosis	08/01
Cabaletta Bio Receives Additional FDA Fast Track Designations for CABA-201 in Dermatomyositis and Systemic Sclerosis	08/01
Cabaletta Bio, Inc. Receives Additional FDA Fast Track Designations for CABA-201 in Dermatomyositis and Systemic Sclerosis	08/01
Cabaletta Bio to Present at the 42nd Annual J.P. Morgan Healthcare Conference	02/01
Cabaletta Bio, Inc.(NasdaqGS:CABA) added to NASDAQ Biotechnology Index	18/12

No hay resultados para esta búsqueda

Todas Recomendaciones analistas Eventos destacados Insiders Transcripts Comunicados Publs. oficiales Otros idiomas Ideas de trading Artículos de MarketScreener Estrategias MarketScreener

Otros idiomas Cabaletta Bio, Inc.

Acciones

CABA

US12674W1099

Otros idiomas

Filtros